Tower Research Capital LLC (Trc) Biovie Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.4 - $0.56 $3,636 - $5,090	9,090 Added 74.0%	21,374 $8,000
Q1 2024 May 15, 2024	BUY	$0.53 - $1.89 $2,654 - $9,467	5,009 Added 68.85%	12,284 $6,000
Q4 2023 Feb 13, 2024	SELL	$1.22 - $5.24 $18,071 - $77,620	-14,813 Reduced 67.06%	7,275 $9,000
Q3 2023 Nov 14, 2023	BUY	$2.75 - $5.17 $42,776 - $80,419	15,555 Added 238.1%	22,088 $75,000
Q2 2023 Aug 14, 2023	BUY	$4.09 - $8.29 $9,157 - $18,561	2,239 Added 52.14%	6,533 $28,000
Q1 2023 May 09, 2023	BUY	$4.89 - $10.53 $20,249 - $43,604	4,141 Added 2706.54%	4,294 $35,000
Q4 2022 Feb 10, 2023	SELL	$3.86 - $42.0 $22,333 - $243,012	-5,786 Reduced 97.42%	153 $1,000
Q3 2022 Nov 10, 2022	BUY	$1.38 - $25.6 $2,417 - $44,851	1,752 Added 41.84%	5,939 $15,000
Q2 2022 Aug 15, 2022	BUY	$1.44 - $5.04 $4,824 - $16,884	3,350 Added 400.24%	4,187 $6,000
Q1 2022 May 12, 2022	BUY	$2.74 - $5.65 $2,293 - $4,729	837 New	837 $4,000
Q2 2021 Aug 16, 2021	SELL	$10.57 - $21.61 $2,927 - $5,985	-277 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$14.35 - $44.81 $3,974 - $12,412	277 New	277 $5,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $97.1M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.